Business UpdateJul 2, 2026, 04:01 AM
Oculis Management to Present at Piper Sandler Conference
AI Summary
Oculis Holding AG announced that its management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. CFO Sylvia Cheung will present an overview and update of the company's innovative late-stage portfolio. Key highlights include Privosegtor, a neuroprotective candidate with FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis, targeting a $7B+ market, and Licaminlimab, a topical anti-TNFα in a registrational trial for dry eye disease. The company emphasized its strong balance sheet and advanced pipeline, positioning it for value-driving milestones.
Key Highlights
- Oculis management to participate in Piper Sandler Virtual Ophthalmology Conference on July 10.
- CFO Sylvia Cheung will present in a fireside chat at 9:30 AM ET.
- Company will provide an overview and update on its late-stage portfolio.
- Privosegtor received FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis.
- Privosegtor targets an estimated potential market opportunity of $7B+ in the U.S. alone.
- Licaminlimab is being evaluated in the PREDICT-1 registrational trial for dry eye disease.
- Oculis highlights its strong balance sheet and advanced pipeline.
Price Impact
More from OCS